UB Paderborn / Katalog / Suche / in CDI

Clinical risk predictors in atrial fibrillation patients following successful coronary stenting: ENTRUST-AF PCI sub-analysis

Clinical research in cardiology, 2021-06, Vol.110 (6), p.831-840

2021

Volltextzugriff (PDF)

The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study

Orphanet journal of rare diseases, 2021-04, Vol.16 (1), p.191-191, Article 191

2021

Volltextzugriff (PDF)

Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study

European heart journal. Cardiovascular pharmacotherapy, 2021-04, Vol.7 (Supplement_FI1), p.f30-f39

2021

Volltextzugriff (PDF)

The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design

Clinical cardiology (Mahwah, N.J.), 2019-12, Vol.42 (12), p.1147-1154

2019

Volltextzugriff (PDF)

Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)

BMC cardiovascular disorders, 2019-07, Vol.19 (1), p.165-165, Article 165

2019

Volltextzugriff (PDF)

The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry

Thrombosis research, 2017-09, Vol.157, p.181-188

2017

Volltextzugriff (PDF)

The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction

Journal of hypertension, 2001-06, Vol.19 Suplement 1 (1), p.S21-S32

2001

Volltextzugriff (PDF)

Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial

The Lancet (British edition), 2019-10, Vol.394 (10206), p.1335-1343

2019

Volltextzugriff (PDF)

Original Research: Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study

Therapeutic advances in cardiovascular disease, 2007-12, Vol.1 (2), p.97-106

2007

Volltextzugriff (PDF)

Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study

Thrombosis journal, 2018-05, Vol.16 (1), p.9-9, Article 9

2018

Volltextzugriff (PDF)

Correction to: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study

Thrombosis journal, 2018-05, Vol.16 (1), p.18-18, Article 18

2018

Volltextzugriff (PDF)

Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial

European heart journal, 2020-12, Vol.41 (47), p.4497-4504

2020

Volltextzugriff (PDF)

Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT‐AF/VTE study

Clinical cardiology (Mahwah, N.J.), 2020-07, Vol.43 (7), p.769-780

2020

Volltextzugriff (PDF)

Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe study

International journal of cardiology, 2024-08, Vol.408, p.132118, Article 132118

2024

Volltextzugriff (PDF)

Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry: A 2-Year Analysis of Patient-Reported Outcomes and Treatment Strategies

The oncologist (Dayton, Ohio), 2023-06, Vol.28 (6), p.e425-e435

2023

Volltextzugriff (PDF)

A prospective real‐world study of the diffuse‐type tenosynovial giant cell tumor patient journey: A 2‐year observational analysis

Journal of surgical oncology, 2022-12, Vol.126 (8), p.1520-1532

2022

Volltextzugriff (PDF)

Patient journey and quality of life (QOL) among diffuse-type TGCT in the U.S

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e23565-e23565

2020

Volltextzugriff (PDF)

Efficacy and Safety of Triple Antihypertensive Therapy with the Olmesartan/Amlodipine/Hydrochlorothiazide Combination

Clinical drug investigation, 2012-10, Vol.32 (10), p.1

2012

Volltextzugriff (PDF)

Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer

Future oncology (London, England), 2024-06, Vol.20 (18), p.1237-1250

2024

Volltextzugriff (PDF)

Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF

International journal of cardiology, 2017-04, Vol.232, p.98-104

2017

Volltextzugriff (PDF)

ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months

Thrombosis research, 2020-12, Vol.196, p.297-304

2020

Volltextzugriff (PDF)

Efficacy and Safety of Triple Antihypertensive Therapy with the Olmesartan/Amlodipine/Hydrochlorothiazide Combination

Clinical drug investigation, 2012-10, Vol.32 (10), p.649-664

2012

Volltextzugriff (PDF)

Open-Label Study Assessing the Long-term Efficacy and Safety of Triple Olmesartan/Amlodipine/Hydrochlorothiazide Combination Therapy for Hypertension

Advances in therapy, 2014-05, Vol.31 (5), p.561-574

2014

Volltextzugriff (PDF)

Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care

European heart journal. Cardiovascular pharmacotherapy, 2023-01, Vol.9 (1), p.47-57

2023

Volltextzugriff (PDF)

ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries

European journal of internal medicine, 2020-12, Vol.82, p.48-55

2020

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Clinical risk predictors in atrial fibrillation patients following successful coronary stenting: ENTRUST-AF PCI sub-analysis

The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study

Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study

The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design

Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)

The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry

The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction

Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial

Original Research: Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study

Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study

Correction to: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study

Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial

Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT‐AF/VTE study

Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe study

Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry: A 2-Year Analysis of Patient-Reported Outcomes and Treatment Strategies

A prospective real‐world study of the diffuse‐type tenosynovial giant cell tumor patient journey: A 2‐year observational analysis

Patient journey and quality of life (QOL) among diffuse-type TGCT in the U.S

Efficacy and Safety of Triple Antihypertensive Therapy with the Olmesartan/Amlodipine/Hydrochlorothiazide Combination

Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer

Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF

ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months

Efficacy and Safety of Triple Antihypertensive Therapy with the Olmesartan/Amlodipine/Hydrochlorothiazide Combination

Open-Label Study Assessing the Long-term Efficacy and Safety of Triple Olmesartan/Amlodipine/Hydrochlorothiazide Combination Therapy for Hypertension

Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care

ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries

Suchergebnisse filtern